Lexagene Holdings (Lexagene Holdings) Total Liabilities : $2.22 Mil (As of Nov. 2022)

View and export this data going back to 2017. Start your Free Trial

What is Lexagene Holdings Total Liabilities?

Lexagene Holdings's Total Liabilities for the quarter that ended in Nov. 2022 was $2.22 Mil.

Lexagene Holdings's quarterly Total Liabilities declined from May. 2022 ($1.72 Mil) to Aug. 2022 ($1.64 Mil) but then increased from Aug. 2022 ($1.64 Mil) to Nov. 2022 ($2.22 Mil).

Lexagene Holdings's annual Total Liabilities increased from Feb. 2020 ($2.13 Mil) to Feb. 2021 ($2.31 Mil) but then declined from Feb. 2021 ($2.31 Mil) to Feb. 2022 ($1.82 Mil).

Lexagene Holdings Total Liabilities Historical Data

The historical data trend for Lexagene Holdings's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lexagene Holdings Total Liabilities Chart

Lexagene Holdings Annual Data

Trend

Mar13

Mar14

Mar15

Feb16

Feb17

Feb18

Feb19

Feb20

Feb21

Feb22

Total Liabilities

Get a 7-Day Free Trial

0.26

0.32

2.13

2.31

1.82

Lexagene Holdings Quarterly Data
	Feb18	May18	Aug18	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22
Total Liabilities	Get a 7-Day Free Trial															1.61	1.82	1.72	1.64	2.22

Lexagene Holdings Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Lexagene Holdings's Total Liabilities for the fiscal year that ended in Feb. 2022 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	0.923	+	(0.896	+	-1.1102230246252E-16
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	1.82

Total Liabilities	=	Total Assets (A: Feb. 2022 )	-	Total Equity (A: Feb. 2022 )
	=	8.198	-	6.38
	=	1.82

Lexagene Holdings's Total Liabilities for the quarter that ended in Nov. 2022 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1.655	+	(0.561	+	0.001
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	2.22

Total Liabilities	=	Total Assets (Q: Nov. 2022 )	-	Total Equity (Q: Nov. 2022 )
	=	3.49	-	1.273
	=	2.22

Lexagene Holdings Total Liabilities Related Terms

Thank you for viewing the detailed overview of Lexagene Holdings's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Lexagene Holdings (Lexagene Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lexagene Holdings Inc (OTCPK:LXXGQ) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

500 Cummings Center, Suite 4550, Beverly, MA, USA, 01915

Website

https://www.lexagene.com

Lexagene Holdings Inc is a molecular diagnostics company that develops molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for on-site rapid testing in veterinary diagnostics, and for use in open-access markets such as food and water safety, clinical research, agricultural testing and biodefense. The MiQLab system delivers sensitivity, specificity, and breadth of detection and can return results in approximately two hours. The unique open-access feature is designed for custom testing so that end-users can load their own real-time PCR assays onto the instrument to target any genetic target of interest.